Marburg acute multiple sclerosis

Source: Wikipedia, the free encyclopedia.
Marburg acute multiple sclerosis
Other namesAcute multiple sclerosis, Marburg type
Main symptoms of Multiple sclerosis.

Marburg acute multiple sclerosis, also known as Marburg multiple sclerosis or acute fulminant

neuromyelitis optica (NMO), Balo concentric sclerosis, and Schilder's disease.[1] The graver course is one form of malignant multiple sclerosis, with patients reaching a significant level of disability in less than five years from their first symptoms, often in a matter of months.[2]

Sometimes Marburg MS is considered a synonym for

tumefactive MS,[3] but not for all authors.[citation needed
]

Pathogenesis

Marburg MS has been reported to be closer to

anti-MOG associated ADEM than to standard MS[4] It has been reported to appear sometimes post-partum[5]

MOG antibody‐associated demyelinating pseudotumor

Main article:
anti-MOG associated encephalomyelitis

Some

anti-MOG cases satisfy the MS requirements (lesions disseminated in time and space) and are therefore traditionally considered MS cases. After the discovery of the anti-MOG disease this classification is into revision.[6]

Diagnosis

It took its name from

MRI scan.[7]
If Marburg disease occurs in the form of a single large lesion, it can be radiologically indistinguishable from a brain tumor or abscess. It is usually lethal, but it has been found to be responsive to
autologous stem cell transplantation.[10] Recent evidence shows that Marburg's presents a heterogeneous response to medication, as does standard MS.[11]

Treatment

Historically, acute MS was a fatal disease, with death occurring within a year of onset, often secondary to extensive brainstem demyelination. Treatments include plasma exchange and/or high-dose glucocorticoids(e.g., 1 g/day of methylprednisolone for 3-5 days). Patients that satisfy criteria for MS will be treated with immunomodulatory therapies, often favoring high efficacy monoclonal antibodies.

Prognosis

Marburg variant of MS is an acute fulminant demyelinating process which in most cases progresses inexorably to death within 1–2 years.[12] However, there are some reports of Marburg MS reaching stability by three years.[13]

See also

References

  1. PMID 11787357
    .
  2. S2CID 40213123
    .
  3. ^ See explanation at
  4. ^ Todd A Hardy, Reddel, Barnett, Palace, Lucchinetti, Weinshenker, Atypical CNS inflammatory demyelinating disease, The lancet neurology, August, 2016, DOI:https://doi.org/10.1016/S1474-4422(16)30043-6, Manuscript Number: THELANCETNEUROLOGY-D-16-00113R1 available at [1]
  5. ^ Eduardo Labat et al., An extremely aggressive case of Marburg's disease treated with high dose cyclophosphamide. A case report, Multiple Sclerosis and Related Disorders, Volume 31, June 2019, Pages 51-53, https://doi.org/10.1016/j.msard.2019.03.014
  6. ^ Yaqing Shu Youming Long Shisi Wang Wanming Hu Jian Zhou Huiming Xu Chen Chen Yangmei Ou Zhengqi Lu Alexander Y. Lau Xinhua Yu Allan G. Kermode Wei Qiu, Brain histopathological study and prognosis in MOG antibody‐associated demyelinating pseudotumor, 08 January 2019, https://doi.org/10.1002/acn3.712
  7. S2CID 12897512
    .
  8. S2CID 30709186
    .
  9. ^ Gormley KM, Zajicek JP (2006). "Alemtuzumab and craniotomy for severe acute demyelinating illness". 16th Meeting of the European Neurological Society. Archived from the original on 2007-10-07.
  10. S2CID 42334384
    .
  11. S2CID 38328163
    .
  12. ISBN 9780071748896
    .
  13. S2CID 37354295
    .

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Marburg_acute_multiple_sclerosis&oldid=1189654036"